Navigation Links
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Date:12/16/2009

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated with the inflammation underlying certain autoimmune diseases, including RA. By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients and inhibiting the subsequent joint destruction while minimizing the potential for off-target effects, thus providing a wider therapeutic window than currently approved therapies. The high potency and selectivity of the molecule are expected to provide continuous receptor coverage throughout the dosing period which is thought to be critical for efficacy. Successful completion of single and multiple ascending dose Phase 1 studies in healthy volunteers showed that CCX354 was safe and well-tolerated.

"Initiation of a Phase 2 clinical development program for CCX354 marks yet another important milestone for ChemoCentryx and represents a unique opportunity to thoroughly evaluate a new mechanism of action for the potential treatment of rheumatoid arthritis," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We believe our CCR1 antagonist is best-in-class, surpassing the properties of previous molecules in this space, particularly in its ability to continuously cover the disease target, the CCR1 receptor. This study builds on our recent clinical success of demonstrating efficacy for Traficet-EN(TM), a novel drug which targets another chemokine receptor, in patients suffering from Crohn's disease. We
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
2. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
9. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
10. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... device has been shown to reduce seizures in patients ... When coupled with an innovative electrode placement planning system ... complete elimination of seizures in nearly half of the ... , That,s good news for a large portion of ... epilepsy whose seizures can,t be controlled with medications and ...
(Date:4/22/2014)... at UT Southwestern Medical Center are making breakthroughs that ... A team of physician-scientists at UT Southwestern has ... with natural anti-depressant properties) works inside the brain. Simultaneously, ... depression in the form of a neuroprotective drug known ... in April,s issue of Molecular Psychiatry, is ...
(Date:4/22/2014)... for Molecular Pathology (AMP) released a report today ... on recommendations for a molecular diagnostics curriculum at ... The report was prepared by the Medical Laboratory ... Training and Education Committee. "Our goal was to ... laboratory scientists appropriately in order to manage the ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... WEST PALM BEACH, Fla., Aug. 25 For years, millions ... pantyhose to cover up unsightly varicose and spider veins. Now there,s ... Garden of Life,s ( www.gardeno f life.com ... clinical studies and millions of happy European women. , , ...
... ORLEANS, Aug. 25 Over 102,000 Americans are ... and a Slidell, Louisiana resident is making the most of his ... for the 2010 Transplant Olympics, twittering his progress, and furthering his ... a unique and personal level of hope and understanding by caring ...
... Study Suggests Division, Ambivalence and Hesitancy to Change; Demographics ... Aug. 25 Americans lack confidence that healthcare reform will deliver ... released today by the Thomson Reuters. , , ... a wide range of issues including the cost and quality of ...
... ... the aging eye , ... Francisco, CA (Vocus) August 25, 2009 -- EyeCare America, a national non-profit organization that provides ... a healthy aging eye in honor of September,s Save Your Sight Month., , , , ...
... ... of Honolulu are celebrating the fifth anniversary of their successful partnership by holding an ... ... healthcare education company, and Kapi,olani Community College of Honolulu are celebrating the fifth anniversary ...
... ... honest and forthright look at why Americans are overweight, overwhelmed, and confused, and ... ... (PRWEB) August 25, 2009 -- The question is not whether Americans are getting ...
Cached Medicine News:Health News:Garden of Life Launches Lovely Legs(TM) to Reduce Visible Signs of Varicose and Spider Veins 2Health News:Double Recipient Twitters Transplant Olympic Training and Tackles Nursing School 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 2Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 4Health News:Career Step and Kapi'olani Community College Celebrate Five Year Partnership 2Health News:The Naked Truth: Overweight, Overwhelmed and Confused 2
A full function instrument at an economical price....
... The ophthalmoscope with superior aspherical optics. ... by means of the aspherical optical system ... Beta 200 allows you to view the ... retina even with a small pupil. Conventional ...
The world's first automatic computation program analyzes massive amount of measurement data and computes "the most comfortable value" for the patient....
... Rx Master is designed and ... reliable service and give the ... improve procedures. It embodies the ... want most, including accuracy, speed, ...
Medicine Products: